Precision medicine built on sequenced clinical and molecular data.
Tempus AI sequences tumours and links molecular results to de-identified clinical records, selling diagnostics to oncologists and data products to pharmaceutical companies for trial design and target discovery.
Open roles moved from 113 to 142 over the trailing 30 days, with data engineer roles leading the increase.
A sustained increase at this rate usually precedes headcount growth by one to two quarters.
Median posted compensation for data engineer roles moved from about $171K to $190K across 110 observed postings and reports.
Pay moving this fast usually signals a supply shortage rather than a general raise.
Estimated employees moved from 2,491 to 2,700 across the trailing 90 days, based on public profile and directory changes.
Steady headcount growth, consistent with planned expansion rather than a step change.
The clearance covers an expanded indication, allowing broader reimbursement for the test.
Reimbursement expansion converts clinical validation into revenue.
No competitors detected yet.
No investment relationships tracked.